Boehringer Ingelheim

News

Boehringer moves obesity therapy into phase 3

Boehringer Ingelheim and Zealand Pharma have kicked off three phase 3 trials of obesity drug candidate survodutide, in patients with and without diabetes, in the hope of b

News

Boehringer backs NHS trust programme for diabetics

An alliance between German pharma group Boehringer Ingelheim and an NHS trust in the UK has been launched with the aim of reducing recurring heart attacks in people with d

News

Boehringer preps phase 3 for dual-action obesity drug

Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year.

News

Boehringer moves liposarcoma drug into pivotal trial

Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma (DDLPS), a rare cancer with l

News

Jardiance cleared in EU for CKD, challenging Forxiga

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the

News

So it begins: Next Humira biosimilars launch in US

This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many months after Amgen’s Amjevita (adalimumab-atto) was released in the

Boehringer moves obesity therapy into phase 3

Boehringer backs NHS trust programme for diabetics

Boehringer preps phase 3 for dual-action obesity drug

Boehringer moves liposarcoma drug into pivotal trial

Jardiance cleared in EU for CKD, challenging Forxiga

So it begins: Next Humira biosimilars launch in US

On the future of AI in life sciences, with women at the helm

How to meet your physicians where they are online

Boehringer Ingelheim

Editor's Picks